Radiation Dose in Humans From Orally Administered Tc99m-Heparin
Status:
Completed
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This is a research study of a new agent used for evaluation of inflammation in the GI tract.
This agent is investigational and thus is being studied to determine appropriate dosing and
administration in both normal controls (i.e. people without gastrointestinal complaints) and
patients with eosinophilic disease (i.e. those with an immune reaction and inflammation in
their bodies with a certain cell called an eosinophil).
The study will test whether the radiolabeled agent will bind to the inflammation of
eosinophilic esophagitis patients because an animal model of eosinophilic esophagitis which
shows the striking deposition of eosinophil granule proteins is not available.